Biogen, Sage

Sage rejects Biogen's $469 million takeover offer
Sage Therapeutics said on Monday that its board has unanimously rejected the takeover offer it received from Biogen. The company said Biogen's offer to buy all outstanding shares of Sage that it does not already own for $7.
Sage Rejects Biogen’s Unsolicited Offer, Will Seek Strategic Alternatives
Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the embattled biotech at just $469 million.
Sage rejects Biogen’s buyout offer, but says it's open to deals
Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen Inc.
Sage Rejects Biogen’s Takeover Offer, Will Explore Options
Sage Therapeutics Inc. rejected a takeover offer from drugmaker Biogen Inc. and said it has started exploring possible options including a sale.
Sage Sues Partner Biogen After Unsolicited Takeover Offer
Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital Markets.
Sage rejects Biogen's $469 million takeover offer, says offer undervalues company
Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve shareholders' best interests.
Sage Rejects Biogen Bid, Launches Review of Alternatives
Sage Therapeutics has rejected a buyout bid from partner Biogen and launched a review of strategic alternatives. Sage on Monday said its board determined that Biogen's $7.22-a-share proposal significantly undervalues the biopharmaceutical company and isn't in the best interest of its shareholders.
Sage Therapeutics rejects Biogen bid, starts strategic review
Sage Therapeutics rejected a takeover offer from Biogen and said it started a process to review its strategic alternatives. Sage rose 5.6%. Sage's board will look at
ENDPOINTS NEWS36m
Sage turns down Bio­gen's buy­out of­fer and will look at oth­er op­tions
Sage Therapeutics rejects Biogen's $469M buyout offer. CEO Barry Greene and board seek alternatives, with Goldman Sachs ...
FiercePharma6d
Sage sues Biogen as analyst detects little interest in buyout at original offer price
Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience ...
How to Harvest Sage for a Continuous Supply of Delicious Herbs, According to Gardening Experts
To store fresh sage, wrap it in a damp paper towel, place it in a plastic bag or container, and store it in the refrigerator ...
Sage Therapeutics: Looks Like A 'Strong Buy' With Zurzuvae's Potential And Biogen's Bid
Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Read why I think SAGE ...
‘Recalibrated’ Sage Hill girls basketball races past Portola to extend winning streak
Amalia Holguin, Addison Uphoff and Kamdyn Klamberg combine for 47 points as Sage Hill wins its sixth straight game.
TechRadar14h
Sage Discount Codes for January 2025
Does Sage offer free delivery? Yes, Sage offers free delivery on all orders over £10 which takes up to 3-4 working days. However, non-mainland UK do not qualify for free delivery. Sage offers ...
bovnews1h
Why Did SAGE Therapeutics Inc (SAGE) Stock Surge 1.87% Last Week?
SAGE Therapeutics Inc (SAGE) stock saw a modest uptick, ending the day at $7.1 which represents a slight increase of $0.08 or 1.14% from the prior close of $7.02. The stock opened at $7.02 and touched ...
Sage Group falls Friday, still outperforms market
Sage Group PLC SGE shares inched down 0.49% to £13.30 Friday, on what proved to be an all-around poor trading session for the ...